In neonatal Wistar rats injected with streptozotocin (STZ) at birth (n0-STZ model), a recognized
model of β-cell regeneration, we investigated the capacity of early treatment with glucagon…

In the Goto-Kakizaki (GK) rat, a genetic model of type 2 diabetes, the neonatal β-cell mass
deficit is considered to be the primary defect leading to basal hyperglycemia, which is …

Thiazolidinediones are potent antidiabetic compounds, in both animal and human models,
which act by enhancing peripheral sensitivity to insulin. Thiazolidinediones are high-affinity …

Imeglimin is an investigational first‐in‐class novel oral agent for the treatment of type 2 diabetes
(T2D). Several pivotal phase III trials have been completed with evidence of statistically …

Non-insulin-dependent diabetes (NIDDM) was obtained in adult rats following a neonatal
streptozotocin injection. Rats with NIDDM exhibited slightly lowered plasma insulin, slightly …

Pancreatic islet β-cell dysfunction is characterized by defective glucose-stimulated insulin
secretion (GSIS) and is a predominant component of the pathophysiology of diabetes. …

Background Inflammation followed by fibrosis is a component of islet dysfunction in both
rodent and human type 2 diabetes. Because islet inflammation may originate from endothelial …

Purpose : Erectile dysfunction is highly prevalent in type II diabetes mellitus. Low intensity
extracorporeal shock wave therapy improves erectile function in patients with erectile …

Objectives Type 2 diabetes (T2D) is driven by progressive dysfunction and loss of pancreatic
β‐cell mass. Imeglimin is a first‐in‐class novel drug candidate that improves glycaemia and …

Grb14 is an effector of insulin signaling, which directly inhibits insulin receptor catalytic activity
in vitro. Here, we investigated whether the expression of Grb14 and its binding partner ZIP …